Two medications often used for treatment of immune-mediated conditions, hydroxychloroquine and chloroquine, have recently attracted widespread interest as potential therapies for coronavirus disease 2019. The authors of this commentary provide guidance for clinical decision making for patients with coronavirus disease 2019 as well as for patients with rheumatologic conditions, such as systemic lupus erythematosus and rheumatoid arthritis
Keywords: Antimalarials; Blood plasma; COVID-19; Chloroquine; Clinical trials; Decision making; Drugs; Lupus erythematosus; Metastasis; Pulmonary diseases.